Ondansetron (Zofran) 32 mg, single intravenous (IV) dose: Product removal due to potential for serious cardiac risks

0

Intravenous news: The FDA report “FDA is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks.”

Main page

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.